Toggle navigation
Home
Search
Services
Blog
Contact
About
Complement Activation and Cardiopulmonary Bypass
Rollins, Scott A.
Alexion Pharmaceuticals, Inc., Cheshire, CT, United States
Search 17 grants from Scott Rollins
Search grants from Alexion Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Bioactivity and mechanistic studies using a comprehensive and well characterized
Thermogenetic Tools for Manipulating Neuronal Activity in Mammals
Global Gene Regulatory Networks for Specific Cell Types of the Sea Urchin Embryo
Role of Mismatch Repair in Sporadic Tumor Suppression
CyberInfrastructure for Remote Sensing of Ice Sheets: REU Site (CReSIS-REU)
Recently added grants:
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
Coordinating center for the NCI small cell lung cancer research consortium
Mechanisms coupling DEK to oncogenesis
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.
Screening small molecules for rhabdomyosarcoma fusion proteins
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL052365-03
Application #
2029136
Study Section
Special Emphasis Panel (ZRG4-HEM-2 (02))
Project Start
1994-09-30
Project End
1997-08-31
Budget Start
1996-09-05
Budget End
1997-08-31
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Alexion Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Cheshire
State
CT
Country
United States
Zip Code
06410
Related projects
NIH 1996
R44 HL
Complement Activation and Cardiopulmonary Bypass
Rollins, Scott A. / Alexion Pharmaceuticals, Inc.
NIH 1995
R44 HL
Complement Activation and Cardiopulmonary Bypass
Rollins, Scott A. / Alexion Pharmaceuticals, Inc.
Comments
Be the first to comment on Scott Rollins's grant